Evidence map›Paper›PMID 39785129›Full record

ArticleFuture oncology (London, England)2025

Real-world treatment patterns in patients with non-metastatic non-small cell lung cancer in Greece: the 'EVIDENCE' study.

Giannis Mountzios, Sofia Lampaki, Helena Linardou, Vassilis Georgoulias, Dimitrios Mavroudis, Stavros Anevlavis, Andriani Charpidou, Maria Lykka, Dionysis Spyratos, Evangelos G Sarris and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Future oncology (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Giannis MountziosFourth Oncology Department and Clinical Trials Unit, Henry Dunant Hospital Center, Athens, Greece.ORCID 0000-0002-7780-7836
Sofia LampakiPulmonary Department, General Hospital 'G. Papanikolaou', Aristotle University of Thessaloniki, Thessaloniki, Greece.
Helena LinardouFourth Oncology Department and Comprehensive Clinical Trials Center, Metropolitan Hospital, Athens, Greece.
Vassilis GeorgouliasFirst Department of Medical Oncology, Metropolitan General, Athens, Greece.
Dimitrios MavroudisDepartment of Medical Oncology, University Hospital of Heraklion, Crete, Greece.
Stavros AnevlavisDepartment of Pulmonology, University Hospital of Alexandroupolis, Alexandroupolis, Greece.
Andriani CharpidouOncology Unit, 3rd Department of Internal Medicine, National and Kapodistrian University of Athens, Athens, Greece.ORCID 0000-0002-5107-6430
Maria LykkaFourth Oncology Department and Clinical Trials Unit, Henry Dunant Hospital Center, Athens, Greece.
Dionysis SpyratosPulmonary Department, General Hospital 'G. Papanikolaou', Aristotle University of Thessaloniki, Thessaloniki, Greece.
Evangelos G SarrisFourth Oncology Department and Comprehensive Clinical Trials Center, Metropolitan Hospital, Athens, Greece.
Alvertos SomarakisMedical Affairs Department, AstraZeneca, Athens, Greece.
Christina PapistaMedical Affairs Department, AstraZeneca, Athens, Greece.
Alexandros GlentisMedical Affairs Department, AstraZeneca, Athens, Greece.ORCID 0000-0002-4055-3713
Aristeidis NikolaouMedical Affairs Department, AstraZeneca, Athens, Greece.
Zoe PaparepaClinical Operations, AstraZeneca, Athens, Greece.
Foteini PapageorgiouDiagnostics Function Oncology, AstraZeneca, Athens, Greece.
Konstantinos N SyrigosOncology Unit, 3rd Department of Internal Medicine, National and Kapodistrian University of Athens, Athens, Greece.ORCID 0000-0001-8082-594X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe treatment landscape of non-metastatic non-small cell lung cancer (NM-NSCLC) is rapidly evolving with recent approvals of immunotherapies and targeted therapies.

methodsThis retrospective study included 202 adults diagnosed with NM-NSCLC between 1 January 2018 and 31 December 2020 primarily aiming to capture initial management strategies.

resultsMost frequent treatment patterns among Stage I/II patients (

conclusionInitial strategy was aligned with contemporary at that time European guidelines, setting a benchmark for understanding the future uptake of new therapies.

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsPractice Patterns, Physicians'AdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsChemotherapy, AdjuvantFemaleGreeceHumansMaleMiddle AgedNeoplasm StagingPneumonectomyRetrospective StudiesChemoradiotherapyconsolidationimmunotherapyincidental findingnon-small cell lung cancerprimary tumor resectionreal-worldStage I-III

Identifiers

PMID39785129
PMCPMC11812321

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.